4.0 Article

Kaposiform Hemangioendothelioma With Kasabach-Merritt Syndrome: A New Indication for Propranolol Treatment

Journal

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 33, Issue 4, Pages E171-E173

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0b013e3182152e4e

Keywords

hemangioendothelioma; Kasabach-Merritt syndrome; beta-blocker; propranolol; vincristine

Ask authors/readers for more resources

Kaposiform hemangioendothelioma is a rare vascular tumor in children. Especially, in association with the Kasabach-Merritt Phenomenon it can be life threatening. The management of these patients is very difficult and an aggressive treatment regime is required. Several multimodality and chemotherapeutic regimens have been described but with variable success and many side effects. We present a 6-week-old boy with Kaposiform hemangioendothelioma and Kasabach-Merritt Phenomenon. Ongoing propranolol treatment with only 4 initial courses of vincristine resulted in a remission that lasted at least 1 year.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available